Millennium Management’s NeuroSense Therapeutics NRSN Stock Holding History

Millennium Management’s Portfolio NRSN Stock Details NRSN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-20,259	Closed	-$68K	–	7358
2022 Q2	$68K	Buy	+20,259	New	+$38.4K	﹤0.01%	6075

Other funds holding NRSN

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

VPIM

Vanguard Personalized Indexing Management Oakland, California $10.2B AUM 34.45% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Carson Wealth (CWM LLC) Omaha, Nebraska $38.1B AUM 19.66% 1-Year Est. Return

Millennium Management's NRSN Position: Q3 2022 in Review

Millennium Management sold out of NeuroSense Therapeutics (NRSN) in Q3 2022, closing a stake of 20,259 shares — an estimated $68K sold.

Millennium Management first reported a position in NRSN in Q2 2022 and held it in 1 quarter. The position peaked at $68K in Q2 2022. 5 funds tracked by Wall St. Rank hold NRSN as of Q3 2022.

Millennium Management reported no remaining NeuroSense Therapeutics position as of Q3 2022 after selling out during the quarter.
Millennium Management sold 20,259 NeuroSense Therapeutics shares in Q3 2022, an estimated $68K.
Millennium Management first reported a position in NeuroSense Therapeutics in Q2 2022 and held it in 1 quarter.
Millennium Management's NeuroSense Therapeutics position peaked at $68K in Q2 2022.
5 funds tracked by Wall St. Rank held NeuroSense Therapeutics as of Q3 2022.

Based on Millennium Management's 13F filing for Q3 2022, filed 14 Nov 2022.